A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate.
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
/ pharmacology
ADP-Ribosylation Factor 6
ADP-Ribosylation Factors
/ antagonists & inhibitors
Actin Cytoskeleton
/ drug effects
Cell Proliferation
/ drug effects
Chlorobenzenes
/ pharmacology
Humans
Male
Muscle Contraction
/ drug effects
Muscle, Smooth
/ physiology
Nitro Compounds
/ chemistry
Norepinephrine
/ pharmacology
Prostate
/ cytology
Prostate-Specific Antigen
/ metabolism
Prostatic Hyperplasia
/ metabolism
Pyrazoles
/ chemistry
Pyrimidinones
/ chemistry
RNA Interference
RNA, Small Interfering
/ metabolism
Stromal Cells
/ cytology
ADP ribosylation factor (ARF)
NAV2729
adrenergic receptor
benign prostatic hyperplasia
benign prostatic hyperplasia (BPH)
lower urinary tract symptoms
lower urinary tract symptoms (LUTS)
molecular pharmacology
pharmacology
prostate
small GTPase
smooth muscle
smooth muscle contraction
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
09 08 2019
09 08 2019
Historique:
received:
08
02
2019
revised:
19
06
2019
pubmed:
28
6
2019
medline:
17
3
2020
entrez:
28
6
2019
Statut:
ppublish
Résumé
Voiding symptoms in benign prostatic hyperplasia (BPH) are driven by prostate smooth muscle contraction and prostate growth. Smooth muscle contraction in the prostate and other organs critically depends on activation of the small monomeric GTPase RhoA and probably Rac1. A role of another GTPase, ADP-ribosylation factor 6 (ARF6), for smooth muscle contraction has been recently suggested by indirect evidence but remains to be proven for any organ. Here, we report effects of NAV2729, an inhibitor with assumed specificity for ARF6, in human prostate tissues and cultured prostate stromal cells (WPMY-1). NAV2729 (5 μm) inhibited neurogenic and α
Identifiants
pubmed: 31243101
pii: S0021-9258(20)30171-X
doi: 10.1074/jbc.RA119.007958
pmc: PMC6690707
pii:
doi:
Substances chimiques
ADP-Ribosylation Factor 6
0
Chlorobenzenes
0
NAV-2729
0
Nitro Compounds
0
Pyrazoles
0
Pyrimidinones
0
RNA, Small Interfering
0
pyrazolo(1,5-a)pyrimidin-7(4H)-one
0
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
76898-47-0
Prostate-Specific Antigen
EC 3.4.21.77
ADP-Ribosylation Factors
EC 3.6.5.2
ARF6 protein, human
EC 3.6.5.2
Norepinephrine
X4W3ENH1CV
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12231-12249Informations de copyright
© 2019 Yu et al.
Références
J Physiol. 2000 Jan 15;522 Pt 2:177-85
pubmed: 10639096
Physiol Rev. 2003 Oct;83(4):1325-58
pubmed: 14506307
J Urol. 2003 Dec;170(6 Pt 1):2517-22
pubmed: 14634463
Cell Signal. 2006 Nov;18(11):1988-94
pubmed: 16650966
Mol Biol Cell. 2007 Feb;18(2):501-11
pubmed: 17122362
Eur Urol. 2007 Jun;51(6):1522-33
pubmed: 17416456
Neurourol Urodyn. 2007 Oct;26(6 Suppl):948-54
pubmed: 17696159
Curr Urol Rep. 2007 Jul;8(4):269-74
pubmed: 18519010
Cardiovasc Res. 2008 Nov 1;80(2):290-8
pubmed: 18599477
Eur Urol. 2009 Apr;55(4):864-73
pubmed: 19027219
Gastroenterology. 2010 Jan;138(1):13-8.e1-3
pubmed: 19931260
Physiology (Bethesda). 2009 Dec;24:342-56
pubmed: 19996365
J Pharmacol Sci. 2010;114(3):239-47
pubmed: 20948164
BJU Int. 2011 Oct;108(7):1132-8
pubmed: 21231991
Handb Exp Pharmacol. 2011;(202):117-48
pubmed: 21290225
Br J Pharmacol. 2011 Jul;163(5):891-907
pubmed: 21410684
Mol Carcinog. 2011 Nov;50(11):901-12
pubmed: 21438025
Mol Med Rep. 2012 Feb;5(2):313-6
pubmed: 22038307
Nat Rev Urol. 2013 Jan;10(1):49-54
pubmed: 23165396
Eur Urol. 2013 Jul;64(1):118-40
pubmed: 23541338
Neurourol Urodyn. 2014 Sep;33(7):1074-85
pubmed: 24038148
Am J Physiol Renal Physiol. 2013 Nov 15;305(10):F1383-90
pubmed: 24049147
Adv Biol Regul. 2014 Jan;54:59-66
pubmed: 24139303
PLoS One. 2014 Sep 12;9(9):e107593
pubmed: 25216271
Eur Urol. 2015 Sep;68(3):418-25
pubmed: 25465970
Small GTPases. 2014;5(4):1-10
pubmed: 25496262
Br J Pharmacol. 2015 Jun;172(11):2905-17
pubmed: 25631101
J Biol Chem. 2016 Feb 19;291(8):3967-81
pubmed: 26703465
PLoS One. 2016 Jan 29;11(1):e0148097
pubmed: 26824355
Nat Rev Dis Primers. 2016 May 05;2:16031
pubmed: 27147135
Cancer Cell. 2016 Jun 13;29(6):889-904
pubmed: 27265506
Br J Pharmacol. 2016 Dec;173(23):3342-3358
pubmed: 27638545
Eur Urol. 2017 Apr;71(4):570-581
pubmed: 27717522
Adv Biol Regul. 2017 Jan;63:115-121
pubmed: 27776975
Prostate. 2017 May;77(7):697-707
pubmed: 28116771
Life Sci. 2017 Aug 1;182:80-84
pubmed: 28625359
Differentiation. 2017 Jul - Aug;96:49-61
pubmed: 28800482
Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F47-F57
pubmed: 28855187
Biochemistry. 2017 Sep 26;56(38):5125-5133
pubmed: 28858527
Eur J Pharmacol. 2018 Jan 5;818:74-83
pubmed: 29055784
J Allergy Clin Immunol. 2018 Sep;142(3):824-833.e3
pubmed: 29155102
Cancer Res. 2019 Jun 1;79(11):2892-2908
pubmed: 31048499